Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-002 in Parkinson's Disease
NCT07005180Phase 2Recruiting
- Sponsor
- Hillhurst Biopharmaceuticals
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBI-002 in Parkinson's disease (PD), sponsored by Hillhurst Biopharmaceuticals. Started Jun 2026; status: recruiting.
02
Drugs
HBI-002
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07005180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005180.